Towards Parkinson’s risk assessment and prognosis through AI
AI-PROGNOSIS is a Horizon Europe research and innovation project that aims to advance Parkinson’s disease diagnosis and care through novel predictive models combined with digital biomarkers from everyday devices.
Co-creation
User research and engagement of key stakeholders over the course of R&D.
18
Partners from the EU and UK
4
Years in duration
3
Multi-centre clinical studies
Our motivation
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, affecting ~10 million people worldwide, and has no cure.
PD is often missed or misdiagnosed, as early symptoms are subtle and common with other diseases. Moreover, selecting the optimal medication regimen is usually a lengthy, “trial and error” process, leading to unnecessary suffering.
Our research
Based on multi-source sets of in-depth health and genetic data, AI-PROGNOSIS aims to develop and validate novel AI models for personalised Parkinson’s disease (PD) risk assessment and prognosis.
PD risk prediction
Based on a person’s relevant characteristics and early signs, measured also with everyday digital devices.
PD progression prediction
In terms of time to higher disability transition, with emphasis on motor impairment and known disease milestones.
Medication response prediction
In terms of reduction of symptoms and of side effects, for a shortlist of common dopaminergic treatments.
Our methodological pillars
Co-creation
Through continuous engagement with key stakeholders, including persons with PD and healthcare professionals, during R&D.
Trustworthy AI
Compliance in practice with Trustworthy and Responsible AI guidelines, including the EU MDR and the upcoming EU AI act.
Clinical validation
Through well-designed, sufficiently-powered studies for proof-of-concept validation of research outcomes and digital tools.
Our envisioned AI tools
Ultimately, AI-PROGNOSIS aims to develop an ecosystem of digital health tools for persons with and without Parkinson’s disease (PD) and healthcare professionals towards better disease screening and care. Driven by the novel AI models, these tools will offer personalised insights into disease risk, progression, and treatment, with the help of data from the smartphone and a smartwatch.
mAI-Health app
For persons with suspected PD to track their personalised risk.
mAI-Care app
For persons with PD to track symptoms, disease progression, and medication efficacy.
mAI-Insights app
Healthcare professionals’ (Web) app for PD screening, patient follow up, and medication regimen optimisation.